AbCellera vs Saama Analytics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms.
About
AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem.
Saama Analytics is the #1 AI clinical analytics platform for life sciences; received up to $430M Carlyle-led investment in May 2025; serves 50+ biotech companies across 1,500+ studies including top-20 pharma.
About
Saama Analytics is the leading AI-driven clinical analytics and data management platform for the life sciences industry, positioning itself as the "#1 in AI Clinical Analytics" based on customer adoption across major pharmaceutical and biotechnology companies. Founded and headquartered in the United States, Saama's Life Science Analytics Cloud (LSAC) platform accelerates clinical trial execution by automating data processing, quality checking, safety signal detection, and regulatory submission preparation — tasks that traditionally require significant manual effort from biostatisticians, data managers, and clinical programmers.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.